The United States Blood Plasma Market is driven by increasing demand for immunoglobulins, albumin, and coagulation factor therapies used in the management of various immune and bleeding disorders. Expansion of plasma donation centers, improvements in collection technologies, and investments in processing capacity are further supporting industry growth.

The Blood Plasma Market was valued at US$44.83 billion in 2025 and is projected to reach US$83.02 billion by 2034, expanding at a CAGR of 8.01% from 2026 to 2034. Growth is being supported by increasing plasma collection capacity, expanding fractionation infrastructure, and wider access to specialty therapies.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00003721

Blood Plasma Market Growth Drivers and Demand Trends

The increasing prevalence and improved diagnosis of primary immunodeficiency, immune thrombocytopenia, hemophilia, chronic inflammatory demyelinating polyneuropathy, and other immune-mediated disorders are creating recurring demand for plasma-derived products. Immunoglobulin remains a major contributor because many patients require long-term replacement or immune-modulating treatment.

Albumin continues to play an important role in critical care, liver disease management, surgery, and volume replacement. Coagulation factors and fibrinogen products remain essential for patients with bleeding disorders. These established clinical applications provide a relatively resilient demand base and support long-term consumption.

Expansion of plasma collection centers is another important growth factor. Manufacturers are investing in automated plasmapheresis, donor engagement platforms, cold-chain systems, and manufacturing optimization to increase plasma yields and improve production efficiency. Because the conversion of collected plasma into finished therapies involves multiple processing and testing stages, supply-chain efficiency remains strategically important.

Regional Analysis and Emerging Opportunities

North America held approximately 49% to 53% share in 2025 and is expected to register a CAGR of 7.6% to 8.4% during 2026 to 2034. The US accounts for the majority of regional demand, supported by a dense network of plasma collection centers, specialty physicians, established reimbursement channels, and extensive use of immunoglobulin and albumin therapies.

Europe represented approximately 24% to 28% share in 2025. Germany, France, Italy, Spain, and the UK are important contributors due to established healthcare infrastructure, fractionation capabilities, hospital procurement, and specialty treatment programs.

Asia Pacific is expected to record the fastest regional expansion, with a projected CAGR of 9.0% to 10.0% during the forecast period. China, Japan, South Korea, India, and Australia are expanding healthcare infrastructure and access to specialty therapies. Government initiatives supporting domestic biologics production and healthcare modernization are also creating opportunities for local partnerships and manufacturing investments.

Component and Application Analysis

The Immunoglobulin segment held approximately 38% to 42% share in 2025, making it the largest component category. Its strong position is attributed to recurring use in primary immunodeficiency, immune-mediated neurological conditions, and other immune disorders. Albumin remains a critical product in hospitals, while coagulation factors address hemophilia and other bleeding conditions.

By application, immunology and hematology represent established demand centers, whereas neurology is among the fastest-growing areas. The neurology segment held approximately 13% to 17% share in 2025 and is projected to grow at a CAGR of 9.4% to 10.2%, supported by increasing diagnosis and treatment of chronic inflammatory neuropathies.

Hospitals and clinics remain the dominant end users because plasma-derived therapies are frequently administered in specialized clinical settings. Research laboratories and academic institutions contribute through clinical studies, disease characterization, diagnostics, and development of new therapeutic applications.

Competitive Landscape

The competitive environment is concentrated among companies with strong plasma collection networks, fractionation capabilities, regulatory expertise, and diversified therapeutic portfolios. Leading participants include:

• CSL Limited
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Kedrion S.p.A.
• LFB S.A.
• Biotest AG
• Sanquin Blood Supply Foundation
• China Biologic Products Holdings, Inc.
• Bio Products Laboratory Ltd.

Companies are focusing on increasing collection capacity, improving manufacturing yields, strengthening specialty product portfolios, and expanding geographic reach. Investments in digital donor management and predictive supply planning are also becoming increasingly relevant as manufacturers seek to reduce supply volatility and improve operational efficiency.

Future Outlook

The Blood Plasma Market is expected to maintain strong growth through 2034 as healthcare systems expand access to immunoglobulin, albumin, coagulation factors, and other plasma-derived therapies. The combination of rising diagnosis of immune and hematological disorders, growing plasma collection capacity, and expanding specialty care will support demand. Asia Pacific and other developing regions are likely to provide significant incremental opportunities, while North America and Europe will remain important due to established treatment ecosystems.

Related Report:

1) Defibrillator Market Key Players and Forecast by 2031

2) Infection Control Market Analysis by Size, Share & Growth 2031

3) Laboratory Water Distiller Market Size, Share & Demand by 2034

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish